Recruiting studies: Metastatic Renal Cell Carcinoma Mrcc

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

PET/CT-Directed Free of Therapy for Metastatic RCC Patients With IMDC Favorable or Intermediate Risk
Phase 2 · 1 location(s) · Jinling Hospital, China · NCT07175480 TDM for Optimized Outcome in Patients With mRCC.
Phase N/A · 1 location(s) · Niels Fristrup · NCT04659343 Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma
Phase 1/Phase 2 · 5 location(s) · Oncorena AB · NCT05287945 Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Met
Phase 1 · 2 location(s) · City of Hope Medical Center · NCT07128680 Radiotherapy in Combination With Checkpoint Inhibition for Patients With Metastatic Kidney Cancer
Phase 2 · 1 location(s) · University of Texas Southwestern Medical Center · NCT06601296 Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Antica
Phase 1/Phase 2 · 128 location(s) · Pfizer · NCT07227415 Axitinib Intensification Plus Nivolumab or Nivolumab Alone After Nivolumab Plus Ipilimumab in mRCC Patients
Phase 2 · 23 location(s) · Consorzio Oncotech · NCT05817903 Urine Omics Predicting IO Therapy Responses in mRCC Patients
Phase N/A · 1 location(s) · National Taiwan University Hospital · NCT04712305 A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal
Phase 2 · 2 location(s) · Brian Rini · NCT07188896 International Multicentric Study ARON-1
Phase N/A · 1 location(s) · Hospital of Macerata · NCT05287464

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.